Hypertension - Persistently high arterial blood pressure. Hypertension may have no known cause (essential or idiopathic hypertension) or be associated with other primary diseases (secondary hypertension). This condition is considered a risk factor for the development of heart disease, peripheral vascular disease, stroke and kidney disease.
Novartis' Exforge, valsartan approved in Europe for patients with high blood pressure
Hypertension :: Novartis' Exforge, valsartan approved in Europe for patients with high blood pressure
Novartis announced today a positive opinion supporting European Union approval of Exforge? (valsartan/ amlodipine besylate) as a new treatment option for patients with high blood pressure.Exforge is the first high blood pressure medication to combine the two most commonly prescribed high blood pressure medicines in their classes - the angiotensin receptor blocker (ARB) valsartan (Diovan?) and the calcium channel blocker (CCB) amlodipine besylate (Norvasc?).
The European Commission generally follows the CHMP's recommendations and is expected to issue a decision within three months. Novartis plans to make Exforge available to patients in Europe in the April 2007. Exforge has also been submitted for US approval earlier this year, and a decision by the US Food and Drug Administration (FDA) is anticipated in the coming months.
"Exforge offers a potential solution to many patients with high blood pressure who currently need two or more medicines to control their illness. This positive opinion for Exforge is highly encouraging since this medicine has been shown to get patients to blood pressure goal with an excellent efficacy and tolerability profile and a reduced pill burden," said James Shannon, MD, Global Head of Development at Novartis Pharma AG.
High blood pressure - and its consequences - is the world's No. 1 killer, estimated by the American Heart Association to affect one in four adults - around one billion people globally. Despite extensive use of current therapies, about 70% of all people with high blood pressure do not reach target blood pressure levels. Many people require two or more medicines to control their blood pressure.
More than 80% of Exforge patients studied reached their recommended blood pressure goals, with reductions in blood pressure of up to 43 mmHg in some groups, according to Phase III data[1] presented at the American Society of Hypertension in May 2006. Exforge also showed a lower incidence of peripheral edema (swelling of the ankles) compared to those taking amlodipine alone.
(Hypertension :: Novartis' Exforge, valsartan approved in Europe for patients with high blood pressure published at SpiritIndia on Saturday, November 18, 2006)
Hypertension
Search more information on Hypertension, Hypertension booksRecently posted related articles on Hypertension :
- Hypertension :: Another Reason to Enjoy Dark Chocolate?
- Portal Hypertension :: Ultra-low-dose aspirin might decrease bleeding severity in portal hypertension
- Liver :: Combination therapy reverses effects of portal hypertension in rats
- Hypertension :: Anger and psychological stress play a role in development of heart disease in prehypertensive middle-aged adults
- Lung :: Placebo use in clinical trials may cause problems in patients with pulmonary hypertension
- Hypertension :: Hypertension appears to be frequently undiagnosed in children and adolescents
- Hypertension :: Understanding hypertension in African Americans proves elusive
- Menopause :: Can post-menopause estrogen loss contribute to obesity/hypertension?
- Kidney :: Kidney failure common among sufferers of hypertension, diabetes
- Hypertension :: Daily bite of dark chocolate reduces blood pressure
Most related articles:
- Hypertension :: Novartis' Exforge, valsartan approved in Europe for patients with high blood pressure- Hypertension :: Valsartan effective in preventing cardiovascular events - JIKEI HEART Study - 15
- Blood Pressure :: Dual renin system blocking drug combo provides additional blood pressure-lowering effects - 14
- Blood Pressure :: Novartis' Tekturna high blood pressure medicine approved in the US - 11.9
- Hypertension :: US beats Europe for hypertension treatment - 11.3
- Hypertension :: Blood pressure monitoring at home - 11.3
- Hypertension :: Better Hypertension control in US than in western Europe - 10.8
- Hypertension :: Precise Logic Wrist Blood Pressure Monitor - 10.4
- Hypertension :: Combination for Blood Pressure Control in hypertensive patients - 9.9
- Blood Pressure :: Tekturna & Diovan together provide additive blood pressure reductions - 9.7
Hypertension - recent related articles/news stories:
- High blood pressure causes memory problems in middle age- Genes linked to blood pressure in African-Americans
- Vegetable proteins lower blood pressure
- Less sleep associated with high blood pressure
- Sicker high blood pressure patients may get best care
»» Macular Degeneration :: Novartis' Lucentis, ranibizumab approved in Europe for severe vision loss
«« Fungal Infections :: Novartis' Mycograb might be approved in Europe for serious fungal infections
The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com